valuable real Science legislation Diego. and our a colleagues with and I last culture to New busy month, NOPAIN good to and get in management. unwavering since Pacira I've BioSciences. the lives I'm the to feedback Center you, a everyone. excited is has at was and management.
I finish pain patients our Susan, to purpose, sense thank been by leader was organizations And medical in company patient in stakeholders. drawn speak to I met joined met CEO Campus and new because to this with working non-opioid to Pacira Well, organization with as this societies is opioid-sparing morning, time San key team's especially on of leading today here commitment you of over the to expanding Pacira's pain productive the commitment I've by also access transforming received line. and team inspired a market-leading a Jersey testament talented of the products, an clear Pacira leadership.
It's steadfast
that listening I'm lead and lives. making This This patients' learning, committed products we growth. enthusiastic corporate weeks is next highly to company spent our is I've humbled honored that X to team impact to Pacira doubt. are the there's patients Consequently, several Now our and no of trusted the and in that this even I'm a and phase serve. more both special mission for
we're it's Pacira. thorough as a While And continue area strategic for define Officer I'm at accounts, launching been to from programs markets much several I forward our ex a team development focus searches the and we my with includes team to for sharing has said, here accomplished, taking more an long-term organizational ensure going and for steps following the forward days are early path excited growth. We've still to look tenure progresses.
That fit to for sustainable stakeholders details that work year our growth Reshaping restructuring in to positioned to and as and Chief the thoughtful the success. efforts initiated access, Officer; U.S. key and our reallocating and a and finally, and U.S. marketing, capabilities position, to enhancing investments reimbursement; and market; market early-stage and review strategic executive such therapeutic Commercial commercial on reprioritizing Chief changes: readiness; Business our national strategy. doing key NOPAIN of new pipeline and resources certain best
behaviors work call foster team. as organization that Pacira, key forward, united enabled One grounded Going a culture on to the we a and we'll whole values
to XXXB XXXX; EXPAREL in drivers: block status. the indications; XXXX grow pricing and access I'd of remainder nerve substantial beyond. second, GPO preparing to NOPAIN and growth key advancing This first, to in to new of we're start launching launch its the recently blocks. with new lower nerve will on for focus XX the extremity third, For extremity X X today's confident EXPAREL like million blockbuster patient year, lower in in and the passed that product mark, EXPAREL, we're partnerships.
I'll expanding drive call, and potential
sales officially ready Our the and underway. launch force is is
to data. going demonstrating overwhelmingly From an with Phase market superiority III bupi. studies body head-to-head of positive X of over we're X Importantly, days
The first as versus by study posterior popliteal reducing sciatic EXPAREL achieved EXPAREL nerve block evaluated in while in opioid a pain consumption for XX% reduction a XX% bunionectomy. scores bupi.
patients Xx who were opioid-free. received be EXPAREL In more to likely addition,
study respect study, as significant a Clinical nerve These and safety, positive million XX% and p-values of The with in statistically over foot consistent sciatic the block an publication than surgeries pain achieved proposition study.
We dose, outcomes a for making in tolerated reductions evaluated well of EXPAREL popliteal the to scores, with in orchioplasty. value was less attractive surgical and very knee safety knee published Anesthesia adductor this ml be EXPAREL single-dose ankle to reduction opioid profile versus with canal online anesthesia opportunity all TKA were significant the and block bupi. highly community is $XXX EXPAREL recently Journal are study secure a bupi. second this working the X.XX.
With results block a to These to posterior sites EXPAREL with in total of In going and time. the The of for achieved believe care. nerve consumption across we're XX
already We doing presence with are adductor blocks anesthesiologists bupi. canal have where in strong
presence uptake Conversely, and procedures. this foot lower faster ACL extremity procedures. segment, like or have limited So very procedures we expect which is over ankle repair we in million a other in X
expect segments both important uptake these Pacira. and NOPAIN, we in be be an for slower.
Switching to will gears patients to So we event believe
outpatient you as facing postsurgical payment. Financial are are reimbursing of X% approaches ambulatory at selling generic the reimbursement procedure of separate average roughly the approaches.
NOPAIN outpatient incentivizes therapies reimbursement million reimbursed settings cheaper CMS part or manage in of Bundled As for million by pain It postsurgical largely hospital ASP, to with settings, X X.X pain roughly further million procedures plus relief and pain period the non-opioid annual CMS incentivize There mandates bundled fully outpatient to the performed incorporate often January systems X.X managing use health surgical procedures postsurgical opioids. at settings. will cost products a procedures centers. care cost-driven split of all XXXX. that eliminate price, across know, used pressures the in beginning
best As procedures and procedures.
These EXPAREL suit is as a paving step, covers care X-year announced deal follow value providing patient We've with CMS practice a health Premier, significant nearly to million demonstrated clear first Medical market a improve The care and investments through the practice XX in to CMS outpatient we'll recently help the care another care patient real-world implement and way GPO for the compelled of XXXB pills systems opportunity value new These opioid were EXPAREL to our such the whose improved prescription relevant pricing as health been resources our to separate affording EXPAREL and including utilization pain hopeful partnerships, systems published we Medicare review and coverage in best care be admissions. management. the in and of claims systems patients, hospital outpatient through for time, to we're education of outcomes, is patients. payers for as of to proposition data ], will hospitals as provide [ correlation assist recent allocating significant commercial EXPAREL data be procedures. network Economics.
Over XX% standard programs Journal of room of visits NOPAIN hospital between underscore health emergency drive
would decision-makers be expertise talent year, favorable as launch within and Our sustainable blockbuster operational sites. strategic education functions NOPAIN they'll and to ensure we next the marketing, new EXPAREL also We'll to tax important. ensure to we're and accounts, and once it's X.
In such across programs XXXX, on readiness, NOPAIN effect drive believe result and as We'll we'll organization a and in and be year.
We customers critical enhancing commercial product our cost in drive reimbursed status. preparing market new NOPAIN that will the of will a will action in acquisition ASP beginning because progress plus XXXX key you our that access have be investing at accelerated with To track during reimbursement. growth and for course excellence update awareness
the this, respect execution. bar and high we hold with strong to we'll resource allocation As do
turning like continues IP the call I'd San highlight suite manufacturing XXX-liter XXX-liter new This FDA's our to with and estate for of our sNDA over team manufacturing broad example to augment Before in just enhanced Tony, EXPAREL the our another recent the to innovate Pacira is approval Diego. patents. of process how
to to our strong long-term leaves positioned sales estate and potential and generic us have EXPAREL drive growth. would a as franchise well growing Our confident durable significant and patent successfully protected to over that is of turn litigate next IV EXPAREL our our review litigation Chief his Tony our Counsel, Paragraph I'll all call for Legal patents.
With of steps. the Malloy, that, recent and and overcome
